Literature DB >> 15990135

Placenta--an alternative source of stem cells.

Tiina Matikainen1, Jarmo Laine.   

Abstract

The two most promising practical applications of human stem cells are cellular replacement therapies in human disease and toxicological screening of candidate drug molecules. Both require a source of human stem cells that can be isolated, purified, expanded in number and differentiated into the cell type of choice in a controlled manner. Currently, uses of both embryonic and adult stem cells are investigated. While embryonic stem cells are pluripotent and can differentiate into any specialised cell type, their use requires establishment of embryonic stem cell lines using the inner cell mass of an early pre-implantation embryo. As the blastocyst is destroyed during the process, ethical issues need to be carefully considered. The use of embryonic stem cells is also limited by the difficulties in growing large numbers of the cells without inducing spontaneous differentiation, and the problems in controlling directed differentiation of the cells. The use of adult stem cells, typically derived from bone marrow, but also from other tissues, is ethically non-controversial but their differentiation potential is more limited than that of the embryonic stem cells. Since human cord blood, umbilical cord, placenta and amnion are normally discarded at birth, they provide an easily accessible alternative source of stem cells. We review the potential and current status of the use of adult stem cells derived from the placenta or umbilical cord in therapeutic and toxicological applications.

Entities:  

Mesh:

Year:  2005        PMID: 15990135     DOI: 10.1016/j.taap.2005.01.039

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  18 in total

1.  Expression of transcriptional factor genes (Oct-4, Nanog, and Sox-2) and embryonic stem cell-like characters in placental membrane of Buffalo (Bubalus bubalis).

Authors:  Kapil Dev; Shiv Kumar Giri; Anil Kumar; Anita Yadav; Birbal Singh; Sanjeev Kumar Gautam
Journal:  J Membr Biol       Date:  2012-04-22       Impact factor: 1.843

Review 2.  Corneal epithelial stem cells in health and disease.

Authors:  Julie T Daniels; Anna R Harris; Chris Mason
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

3.  Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells.

Authors:  Jaichandran Sivalingam; Shruti Krishnan; Wai Har Ng; Sze Sing Lee; Toan Thang Phan; Oi Lian Kon
Journal:  Mol Ther       Date:  2010-04-27       Impact factor: 11.454

4.  Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes.

Authors:  Sachin Kadam; Sudhakar Muthyala; Prabha Nair; Ramesh Bhonde
Journal:  Rev Diabet Stud       Date:  2010-08-10

5.  Phase 1 clinical trial for intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with moderate COVID-19 virus pneumonia: results of stage 1 of the study.

Authors:  Alok Sharma; Rohit Kulkarni; Hemangi Sane; Nilkanth Awad; Abhijit Bopardikar; Anagha Joshi; Sujata Baweja; Mohan Joshi; Chandra Vishwanathan; Nandini Gokulchandran; Prerna Badhe; Mazhar Khan; Amruta Paranjape; Pooja Kulkarni; Arjun K Methal
Journal:  Am J Stem Cells       Date:  2022-06-15

6.  Proteomic profiling of human placenta-derived mesenchymal stem cells upon transforming LIM mineralization protein-1 stimulation.

Authors:  Zhen Zhu; Zhihui Liu; Jingyue Liu; Ming Bi; Taoyuan Yang; Jingyun Wang
Journal:  Cytotechnology       Date:  2014-01-28       Impact factor: 2.058

7.  Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential.

Authors:  Igor Nazarov; Jae W Lee; Eric Soupene; Sara Etemad; Derrick Knapik; William Green; Elizaveta Bashkirova; Xiaohui Fang; Michael A Matthay; Frans A Kuypers; Vladimir B Serikov
Journal:  Stem Cells Transl Med       Date:  2012-05-08       Impact factor: 6.940

8.  Preparation and characterization of polylactide/poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) hybrid fibers for potential application in bone tissue engineering.

Authors:  YueLong Wang; Gang Guo; HaiFeng Chen; Xiang Gao; RangRang Fan; DongMei Zhang; LiangXue Zhou
Journal:  Int J Nanomedicine       Date:  2014-04-17

9.  Endometrial regenerative cells: a novel stem cell population.

Authors:  Xiaolong Meng; Thomas E Ichim; Jie Zhong; Andrea Rogers; Zhenglian Yin; James Jackson; Hao Wang; Wei Ge; Vladimir Bogin; Kyle W Chan; Bernard Thébaud; Neil H Riordan
Journal:  J Transl Med       Date:  2007-11-15       Impact factor: 5.531

10.  Genetically modified human placenta‑derived mesenchymal stem cells with FGF‑2 and PDGF‑BB enhance neovascularization in a model of hindlimb ischemia.

Authors:  Tao Yin; Sisi He; Chao Su; Xiancheng Chen; Dongmei Zhang; Yang Wan; Tinghong Ye; Guobo Shen; Yongsheng Wang; Huashan Shi; Li Yang; Yuquan Wei
Journal:  Mol Med Rep       Date:  2015-07-20       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.